With the news that Giovanni Caforio is handing the baton to Chris Boerner, I think we can say we called this one right. In all seriousness, it's no surprise to us that companies recognize the importance of putting people with deep market access roots into leadership positions. The commercial landscape is only growing more complex.
read full article ›Real Endpoints, the leading market-access platform and advisory firm, announces that four biopharma companies with combined 2022 sales of nearly $8 billion have signed contracts to offer Real Endpoint's RE Assist tool to support Medicare patients in need of deductible and copay assistance. RE Assist provides actionable, comprehensive foundation fund information in a compliant and easy to navigate format.
read full article ›The use of warranties – and more broadly, outcomes-based contracting - is a topic that’s sure to come up in an invitation-only meeting I am co-hosting with Roger Longman and Jeff Berkowitz from Real Endpoints, as well as LEK’s Pierre Jacquet and Orsini’s Nick Calla.
read full article ›Thanks to AMCP for hosting a session on value based contracting in healthcare at this year's annual meeting in San Antonio. The packed house underscored how important it is to find alignment between payers and manufacturers to increase market access for transformative therapies. Thanks to Michael A. Ford, R.Ph. and moderator Dean Hakanson MD for joining Real Endpoints' Jane F. Barlow, MD, MPH, MBA in sharing their views.
read full article ›Having just returned from the Informa Access USA conference, we can confirm that the so-called “specialty carve out” or “alternative funding” tactics being used by third-party brokers remain a hot topic of discussion.
read full article ›At the recent annual meeting of the Muscular Dystrophy Association, Peter Marks, head of the Center for Biologics Evaluation and Research, noted the importance of using the accelerated approval channel for gene therapies: "We can’t be so careful about our approvals under accelerated approval that we prevent potentially lifesaving therapies from getting to market in a timely manner," he said.
read full article ›WOoT! We are very happy to have you on board Denise Wolff!
read full article ›Stop by Booth #110 at Access USA to meet the Real Endpoints team! We're showcasing RE Assist, a tech-enabled platform that simplifies the process of finding copay assistance for Medicare patients.
read full article ›Seems like the biopharma industry, not just Caesar, should beware the ides of March. Yesterday, the Centers for Medicare & Medicaid Services updated its guidance for drug price negotiation under the Inflation Reduction Act clarifying that drugs with the same active ingredients will be groups together even if they are approved under different biologic license applications. That suggests that different formulations (say a sub-cue version of an infusion product developed earlier) would be subject to price negotiation at the earliest date of eligibility.
read full article ›